Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022

2022; European Centre for Disease Prevention and Control; Volume: 27; Issue: 50 Linguagem: Inglês

10.2807/1560-7917.es.2022.27.50.2200882

ISSN

1560-7917

Autores

Yanis Merad, Alexandre Gaymard, Laurent Cotte, Thomas Perpoint, Dulce Alfaiate, Matthieu Godinot, Agathe Becker, O Cannesson, Anne-Sophie Batalla, Fatima Oria-Yassir, Sophie Landré, Florence Morfin, Maude Bouscambert, Florent Valour, Florence Ader, Anne Conrad,

Tópico(s)

Rabies epidemiology and control

Resumo

Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.

Referência(s)